Commentary

Japan’s Drug Innovation Incentive Policies: Policy Challenges Undermine Desired Goals (ENG)

Key Takeaways

  • The Japanese government is actively working to restore drug discovery capabilities, aiming to create a revitalized ecosystem that can contribute to domestic and global drug development.
  • However, these efforts continue to be undermined by remaining constraints on Japan’s rewards for innovation in its drug pricing system – even for novel drugs in key areas like rare diseases and pediatrics, where Japan clearly wants more research and development and faster deployment of innovative remedies.
  • The Asia Group (TAG) assesses that strict cost disclosure requirements, especially the “zero co-factor” rule under the cost-based price calculation method, directly undermine the government’s goal of bringing innovative new pharmaceutical products to the Japanese market, including the targets laid out in the Japanese government’s five-year plan for the development and approval of pediatric and rare disease drugs.
  • The Japanese government should consider either adjustments to these rules or introducing an entirely new way of pricing and rewarding innovative medicines to adequately reflect these products’ value at launch. Such changes will facilitate innovative medicines’ faster entry into Japan, ultimately benefiting patients and contributing to the revitalization of Japan’s drug innovation ecosystem.

Related Posts

TAG China Country Director Han Lin Joins the BBC to Discuss the U.S.-Vietnam Trade Deal, Mexico Remittances, the U.S. “Big Beautiful Bill” and Other Topics
Han Lin, China Country Director at The Asia Group, told the BBC that while the passage of the “Big Beautiful ...
TAG Managing Partner, Amb. Kurt Tong Spoke with Bloomberg on Japan’s Response to Potential U.S. Punitive Action
TAG Managing Partner, Amb. Kurt Tong spoke with bloomberg where we discussed Japan’s potential response to any upcoming U.S. punitive ...
美商亞洲集團宣布陳澍(George Chen)榮升合夥人
華盛頓特區及香港 | 2025年7月1日 – 美商亞洲集團(The Asia Group)欣然宣布陳澍(George Chen)晉升為集團的合夥人。陳澍將繼續領導集團在香港和台北的辦公室,並擔任TAG數位部門的聯席主席。陳澍的晉升充分展示了美商亞洲集團進一步結合頂尖全球視野與泛區域洞察的實力,也體現集團對印度-太平洋地區運營的重視,以及對客戶提供完整策略性解決方案和服務的堅定承諾。
The Asia Group Announces George Chen as Partner
Washington, DC & Hong Kong | July 1, 2025 – The Asia Group (TAG) is excited to announce the promotion ...
Scroll to Top

You Are Applying For:

Japan’s Drug Innovation Incentive Policies: Policy Challenges Undermine Desired Goals (ENG)

Apply Now

Submit the details below, and our HR team member will get in touch with you shortly.

The Asia Group is an equal opportunity employer where an applicant’s qualifications are considered without regard to race, color, religion, sex, national origin, age, disability, veteran status, genetic information, sexual orientation, gender identity or expression, or any other basis prohibited by law. The Asia Group continually seeks to diversify its staff, particularly to broaden opportunities for individuals from demographic groups that are historically underrepresented in the strategic advisory profession.

"*" indicates required fields

1Personal Details
2Questionnaire & Application Materials
3Voluntary Self Identification

Personal Details

Name*
Address*